Abstract
Bringing a breakthrough drug from discovery through development and all the way to the patient is
the most difficult and uncertain challenge that humans attempt. The median time to accomplish
such a breakthrough is ten to fifteen years, and successful programs that take 20-25 years and
many billions of dollars of 100%-at-risk investment are not uncommon. The key to success often
hinges on maintaining momentum and focus over such a long period, when failure can come at any
time in the process and setbacks are to be expected. However, hope is not a strategy, and deciding
which programs deserve this focus and persistence is crucial. This talk will describe in detail the
recognition or creation of so-called “aha moments”, early-stage experiments or observations that
are sufficiently compelling to generate legitimate project momentum and belief necessary to
overcome the many setbacks expected before ultimate success. Key “aha moments” in two drug
programs will be described: 1) discovery and development over the last 25 years of a family of
cystic fibrosis drugs at Vertex Pharmaceuticals that have doubled the expected lifetime of patients
afflicted with this monogenic recessive disease; and 2) discovery and development over the last 15
years at Alkeus Pharmaceuticals of a promising preventative drug therapy now entering Phase III
clinical development for Stargardt’s disease, the third largest monogenic disease and the leading
cause of blindness in children and young adults.
To register: https://form.jotform.com/262884262504359




